ArticleDrug design, development and therapy2025
Levofloxacin-Niflumate Salt Development as a Strategy for Improving Physicochemical Properties and Modulating Antibiotic Potency and Anti-Inflammatory Performance.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This research aimed to develop and characterize a novel levofloxacin-niflumic acid salt, to improve its physicochemical properties, antibiotic potency, and anti-inflammatory effects. Methods: A 1:1 molar ratio salt was synthesized and its crystal structure determined using single-crystal X-ray diffractometry (SCXRD) also characterized using powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FTIR). Scalability was evaluated via neat grinding, solvent-dropped grinding, hot melt mixing, and slurry techniques. Stability under controlled conditions (70-80%RH/25-30°C) was assessed using PXRD, DSC, and HPLC solubility measurements, levofloxacin's antibiotic potency (microdilution), and niflumic acid's anti-inflammatory activity (in vivo in Wistar rats) were also evaluated. Results: SCXRD confirmed the formation of a stable multicomponent salt, levofloxacin-niflumate. The slurry method successfully yielded a homogeneous powder with identical structural characteristics to the single crystal. Notably, the salt demonstrated enhanced physical and chemical stability compared to the individual drugs and their physical mixture. The solubility of niflumic acid was significantly increased, and the salt formation positively influenced both levofloxacin's antibiotic potency and niflumic acid's anti-inflammatory activity. Conclusion: The successful development of the levofloxacin-niflumate salt offers a promising strategy to improve the stability and potency of levofloxacin, along with enhanced niflumic acid solubility that contributes to improved anti-inflammatory action. This enhanced profile suggests the potential for more effective and efficient therapeutic use, which could improve patient compliance given the frequent co-prescription of these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.